Acute myeloid leukemia (AML) is treated today with a combination of intensive chemotherapy, lower-intensity regimens built around venetoclax, drugs that target specific mutations, and, for suitable patients, a stem cell transplant. Which of these a person receives depends mainly on their age and fitness and on the genetic makeup of their leukemia. Navigating the complex landscape of AML means understanding how those pieces fit together, and where research is taking treatment next.
AML is a fast-moving hematologic cancer, so decisions often have to be made within days of diagnosis. This guide walks through the disease, the tests that shape treatment, and the options available now.
What Is Acute Myeloid Leukemia?
AML is a cancer of the blood-forming cells in the bone marrow. Normally, myeloid stem cells mature into red cells, platelets, and infection-fighting white cells such as neutrophils. In AML, immature cells called myeloblasts stop maturing and multiply rapidly.
These blasts crowd out healthy production in the marrow, which is why patients develop low blood counts. If you want a refresher on how that factory normally works, see our overview of the composition and function of bone marrow.
AML is the most common acute leukemia in adults, and it becomes more frequent with age; many patients are diagnosed in their late sixties or older. It can occur in children and younger adults too, though less often.
Causes and Risk Factors
Most cases arise without an obvious cause, from genetic changes acquired during life. Recognized risk factors include:
- Prior chemotherapy or radiation therapy for another cancer (so-called therapy-related AML)
- Earlier blood disorders such as myelodysplastic syndromes or myeloproliferative neoplasms
- Inherited conditions, including Down syndrome and certain germline predisposition syndromes
- Smoking and long-term exposure to benzene
- Increasing age
Symptoms and How AML Is Diagnosed
Symptoms reflect the loss of normal blood cells. Low red cells cause anemia with fatigue and breathlessness; low neutrophils lead to fevers and repeated infections; low platelets cause easy bruising, nosebleeds, or gum bleeding. Some patients also have bone pain, weight loss, or swollen gums.
A complete blood count (CBC) is usually the first clue, often showing anemia and thrombocytopenia with a white count that may be high, normal, or low. Blasts may be visible on the blood smear.
The diagnosis is confirmed with a bone marrow aspirate and biopsy. Under the WHO classification, blasts making up at least 20% of marrow or blood cells establish AML, although certain defining genetic abnormalities allow the diagnosis at lower blast counts.
Why Genetic Testing Matters
The marrow sample is sent for cytogenetics (chromosome analysis) and molecular testing for mutations such as FLT3, NPM1, IDH1, IDH2, and TP53. These results sort patients into risk groups and identify targeted drugs. In my practice, waiting a few days for key mutation results is often worthwhile, because they can change the first-line plan.
| Risk group | Typical genetic examples | General implication |
|---|---|---|
| Favorable | t(8;21), inv(16), NPM1 mutation without FLT3-ITD | Chemotherapy alone may be enough; transplant often reserved for relapse |
| Intermediate | Normal karyotype without favorable or adverse markers | Transplant often considered in first remission |
| Adverse | TP53 mutation, complex karyotype, monosomy 7 | Transplant strongly considered; clinical trials encouraged |
Current Treatments for AML
Treatment is usually described in two phases. Induction aims to clear visible leukemia and achieve remission, and consolidation aims to eliminate the hidden cells left behind. For a broader view of how these choices are weighed, see our guide to leukemia treatment options.
Intensive Chemotherapy
For fit patients, the classic induction regimen is “7+3”: seven days of continuous cytarabine plus three days of an anthracycline such as daunorubicin or idarubicin. Consolidation commonly uses cycles of higher-dose cytarabine.
Several agents can be added based on the leukemia’s features. Midostaurin is combined with 7+3 for FLT3-mutated AML, and gemtuzumab ozogamicin, an antibody that targets the CD33 protein, may be added in some favorable-risk cases. A liposomal formulation of daunorubicin and cytarabine is used for therapy-related AML and AML with myelodysplasia-related changes.
Lower-Intensity Therapy
Many older adults, or those with heart, lung, or kidney problems, cannot safely tolerate 7+3. For them, the BCL-2 inhibitor venetoclax combined with azacitidine or decitabine has become a standard approach. It is given largely as an outpatient but still causes significant drops in blood counts, so close monitoring is needed.
Targeted Therapies
- FLT3 inhibitors: midostaurin and quizartinib with chemotherapy; gilteritinib for relapsed or refractory disease
- IDH inhibitors: ivosidenib and olutasidenib for IDH1 mutations; enasidenib for IDH2 mutations
- Menin inhibitors: a newer class for relapsed AML with KMT2A rearrangements or NPM1 mutations
Acute Promyelocytic Leukemia
One subtype, acute promyelocytic leukemia (APL), is treated differently. It carries a high early risk of bleeding and clotting, so it is a medical emergency, but it responds extremely well to all-trans retinoic acid (ATRA) plus arsenic trioxide, often without conventional chemotherapy.
The Role of Stem Cell Transplantation
An allogeneic hematopoietic stem cell transplant replaces the patient’s marrow with stem cells from a matched donor. Its power lies partly in the donor immune system attacking remaining leukemia cells, the graft-versus-leukemia effect.
Transplant offers the best chance of long-term control for many intermediate- and adverse-risk patients, but it carries real risks, including infection and graft-versus-host disease. Newer reduced-intensity conditioning has made it an option for some older patients who once would not have qualified.
Future Directions in AML Care
Research is moving on several fronts. Measurable residual disease (MRD) testing, which detects leukemia at levels far below what a microscope can see, is increasingly used to guide decisions about transplant and further therapy.
Other active areas include combining venetoclax with targeted agents, maintenance therapy after remission, and immune approaches such as bispecific antibodies and cellular therapies. Designing CAR-T cells for AML has proven harder than for lymphoid cancers because suitable targets are also found on healthy blood-forming cells, and that remains an area of ongoing work.
Because the field changes quickly, asking whether a clinical trial is available is always a reasonable question, at diagnosis and at relapse.
Key Takeaways
- AML is an aggressive marrow cancer that usually needs prompt treatment.
- Bone marrow testing with cytogenetics and mutation analysis drives nearly every treatment decision.
- Fit patients typically receive 7+3 induction; less fit patients often receive venetoclax with a hypomethylating agent.
- Targeted drugs now exist for FLT3, IDH1, IDH2, and some KMT2A or NPM1 changes.
- Stem cell transplant remains the main curative option for higher-risk disease.
Frequently Asked Questions
Is AML curable?
Some patients are cured, particularly younger adults with favorable-risk genetics and those who reach remission and then undergo transplant. For others, the goal is long-term control and good quality of life. Your hematologist can explain what is realistic for your specific genetic profile.
How long does induction chemotherapy take?
The drugs in 7+3 are given over one week, but patients usually stay in hospital for several weeks while blood counts recover. A repeat bone marrow test is then done to check for remission.
Why do some patients not get intensive chemotherapy?
Intensive chemotherapy is very demanding on the heart, kidneys, and immune system. For older or frailer patients, lower-intensity regimens such as venetoclax with azacitidine can offer meaningful responses with fewer severe complications.
What is measurable residual disease?
MRD refers to tiny numbers of leukemia cells remaining after treatment, detected with sensitive flow cytometry or molecular tests. Being MRD-negative is generally a good sign, while persistent MRD may prompt a transplant or additional therapy.
